A phase I and pharmacokinetic study of taladegib, a Smoothened inhibitor, in Japanese patients with advanced solid tumors

Conclusions Taladegib doses of 100 mg and 200 mg, but not the global recommended dose of 400 mg, were well tolerated in this population of Japanese patients with advanced solid tumors.

http://link.springer.com/10.1007/s10637-017-0544-y

Source: Investigational New Drugs - February 17, 2018 Category: Drugs & Pharmacology Source Type: research